---
title: "Mesoridazine - Schizophrenia"
sidebar: mydoc_sidebar
permalink: db00933-mesh-d012559-1.html
toc: false 
---


Path ID: `DB00933_MESH_D012559_1`
{% include image.html url="images/db00933-mesh-d012559-1.png" file="db00933-mesh-d012559-1.png" alt="db00933-mesh-d012559-1" %}

## Concepts

|------------|------|---------|
| Identifier | Name | Type    |
|------------|------|---------|
| DB:DB00933 | Mesoridazine | Drug |
| UniProt:P28223 | 5-hydroxytryptamine receptor 2A | Protein |
| UniProt:P14416 | D(2) dopamine receptor | Protein |
| MESH:D004298 | Dopamine | ChemicalSubstance |
| HP:0000716 | Depressivity | PhenotypicFeature |
| GO:0061527 | Dopamine secretion, neurotransmission | BiologicalProcess |
| MESH:D012559 | Schizophrenia | Disease |
|------------|------|---------|

## Relationships

|---------|-----------|---------|
| Subject | Predicate | Object  |
|---------|-----------|---------|
| Mesoridazine | DECREASES ACTIVITY OF | 5-Hydroxytryptamine Receptor 2A |
| Mesoridazine | DECREASES ACTIVITY OF | D(2) Dopamine Receptor |
| 5-Hydroxytryptamine Receptor 2A | POSITIVELY CORRELATED WITH | Depressivity |
| Depressivity | MANIFESTATION OF | Schizophrenia |
| D(2) Dopamine Receptor | POSITIVELY CORRELATED WITH | Dopamine |
| Dopamine | POSITIVELY CORRELATED WITH | Dopamine Secretion, Neurotransmission |
| Dopamine Secretion, Neurotransmission | AFFECTED BY | Schizophrenia |
|---------|-----------|---------|

Comment: Mesoridazine was withdrawn from the United States market in 2004 due to dangerous side effects, namely irregular heart beat and QT-prolongation of the electrocardiogram.

Reference: [https://go.drugbank.com/drugs/DB00933#mechanism-of-action](https://go.drugbank.com/drugs/DB00933#mechanism-of-action){:target="_blank"}